These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9811484)

  • 1. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.
    Wacher VJ; Silverman JA; Zhang Y; Benet LZ
    J Pharm Sci; 1998 Nov; 87(11):1322-30. PubMed ID: 9811484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
    Zhang Y; Guo X; Lin ET; Benet LZ
    Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.
    Zhang Y; Hsieh Y; Izumi T; Lin ET; Benet LZ
    J Pharmacol Exp Ther; 1998 Oct; 287(1):246-52. PubMed ID: 9765344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
    Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
    Zhang Y; Benet LZ
    Clin Pharmacokinet; 2001; 40(3):159-68. PubMed ID: 11327196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.
    Yumoto R; Murakami T; Nakamoto Y; Hasegawa R; Nagai J; Takano M
    J Pharmacol Exp Ther; 1999 Apr; 289(1):149-55. PubMed ID: 10086998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model.
    Cummins CL; Salphati L; Reid MJ; Benet LZ
    J Pharmacol Exp Ther; 2003 Apr; 305(1):306-14. PubMed ID: 12649383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
    Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
    Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
    J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.
    Johnson BM; Charman WN; Porter CJ
    Drug Metab Dispos; 2003 Sep; 31(9):1151-60. PubMed ID: 12920171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine.
    Suzuki H; Sugiyama Y
    Eur J Pharm Sci; 2000 Nov; 12(1):3-12. PubMed ID: 11121729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
    Dufek MB; Bridges AS; Thakker DR
    Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
    Wandel C; Kim RB; Guengerich FP; Wood AJ
    Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats.
    Li J; Liu Y; Zhang J; Yu X; Wang X; Zhao L
    Drug Des Devel Ther; 2016; 10():3699-3706. PubMed ID: 27895462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of human CYP3A and P-glycoprotein on the absorption of drugs.
    van de Waterbeemd H
    Eur J Pharm Sci; 2000 Nov; 12(1):1. PubMed ID: 11121728
    [No Abstract]   [Full Text] [Related]  

  • 16. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats.
    Konishi H; Sumi M; Shibata N; Takada K; Minouchi T; Yamaji A
    J Pharm Pharmacol; 2004 Oct; 56(10):1259-66. PubMed ID: 15482640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemia-reperfusion through distinct mechanisms between CYP3A and P-glycoprotein in the small intestine.
    Ikemura K; Inoue K; Mizutani H; Oka H; Iwamoto T; Okuda M
    Eur J Pharmacol; 2012 Sep; 690(1-3):192-201. PubMed ID: 22749977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The drug efflux-metabolism alliance: biochemical aspects.
    Benet LZ; Cummins CL
    Adv Drug Deliv Rev; 2001 Oct; 50 Suppl 1():S3-11. PubMed ID: 11576692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
    Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
    Hochman JH; Chiba M; Yamazaki M; Tang C; Lin JH
    J Pharmacol Exp Ther; 2001 Jul; 298(1):323-30. PubMed ID: 11408558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.